Welcome to our dedicated page for American Cry news (Ticker: CRYO), a resource for investors and traders seeking the latest updates and insights on American Cry stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect American Cry's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of American Cry's position in the market.
American CryoStem Corporation (CRYO) announced FDA clearance of its Investigational New Drug (IND) application for ATCell™ to treat Post-Concussion Syndrome (PCS). This Phase I trial aims to evaluate ATCell™'s safety and efficacy, offering hope for athletes and military personnel with limited treatment options. The randomized study will recruit 20 patients diagnosed with PCS, assessing various dosing levels of their own cells. Topline results are expected in 2021, representing a significant milestone in addressing the $48.3 billion annual costs associated with traumatic brain injuries in the U.S.